|

Patritumab deruxtecan Clinical Trials

9 actively recruiting trials across 6 locations

Also known as: HER3-DXd, MK-1022, U3-1402

Other2 trials

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Phase 1/2
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Phase 2

Santa Monica, California2 trials

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021)

Phase 2
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

UCLA Hematology Oncology Santa Monica ( Site 1205)

Phase 1/2

Daphne, Alabama1 trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Southern Cancer Center (SCC) ( Site 8000)

Phase 3

Tucson, Arizona1 trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

Aurora, Colorado1 trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 3016)

Phase 1/2

Clermont, Florida1 trial

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Clermont Oncology Center (Site 0041)

Phase 1/2

Boston, Massachusetts1 trial

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Dana-Farber Cancer Institute ( Site 0050)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.